Shanghai-based pharma company Harbour BioMed has announced the closing of an $85-million Series B financing round led by Singapore sovereign wealth fund GIC.

 The funding round saw participation from new investors China Life Private Equity Investment Company and Vertex Ventures, as well as existing investors AdvanTech Capital and Legend Capital, the startup said in a statement.